MDM-2 antagonists induce p53-dependent cell cycle arrest but not cell death in renal cancer cell lines

Cancer Biology and Therapy

Volumn 10, Issue 12, 2010, Pages 1315-1325

  Tsao, Chun Chui ^a   Corn, Paul G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cell cycle arrest; Cell death; Checkpoint; DNA damage; MDM 2 antagonists; Renal cancer

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; MI 219; NUTLIN 3; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ADRENAL CELL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL ASSAY; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DEATH; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; DNA DAMAGE; EPITHELIUM CELL; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CANCER; KIDNEY EPITHELIUM; KIDNEY TUBULE; MUTATION; PROTEIN EXPRESSION; PROTEIN INDUCTION; SENSITIVITY ANALYSIS;

APOPTOSIS; CARCINOMA, RENAL CELL; CELL CYCLE; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOXORUBICIN; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; IMIDAZOLES; KIDNEY TUBULES, PROXIMAL; MALE; MUTATION; PHOSPHORYLATION; PIPERAZINES; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MDM2; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 78650332047     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.12.13612     Document Type: Article

References (41)

1. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005; 353:2477-90.
2. Levy DA, Slaton JW, Swanson DA, Dinney CP. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol 1998; 159:1163-7.
3. Rini BI. Metastatic renal cell carcinoma: many treatment options, one patient. J Clin Oncol 2009; 27:3225-34.
4. Tannir NM, Thall PF, Ng CS, Wang X, Wooten L, Siefker-Radtke A, et al. A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J Urol 2008; 180:867-72.
5. Pagliaro L, Tannir N, Thall P, Ashe R, Perez C, Jonasch E. Phase II study of bevacizumab, gemcitabine and capecitabine treatment for metastatic or unresectable sarcomatoid renal cell carcinoma (SRCC) [abstract]. In: 2010 Genitourinary Cancers Symposium; 2010 March 5-7; San Francisco, CA: ASCO; 2010. Abstract nr 375.
6. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999; 104:263-9.
7. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74:957-67.
8. El-Deiry WS. The role of p53 in chemosensitivity and radiosensitivity. Oncogene 2003; 22:7486-95.
9. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene 2005; 24:2899-908.
10. Zilfou JT, Lowe SW. Tumor Suppressive Functions of p53. Cold Spring Harb Perspect Biol 2009; 1:1883.
11. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408:307-10.
12. Nenutil R, Smardova J, Pavlova S, Hanzelkova Z, Muller P, Fabian P, et al. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. J Pathol 2005; 207:251-9.
13. Gurova KV, Hill JE, Razorenova OV, Chumakov PM, Gudkov AV. p53 pathway in renal cell carcinoma is repressed by a dominant mechanism. Cancer Res 2004; 64:1951-8.
14. Gurova KV, Hill JE, Guo C, Prokvolit A, Burdelya LG, Samoylova E, et al. Small molecules that reactivate p53 in renal cell carcinoma reveal a NFkappaB-dependent mechanism of p53 suppression in tumors. Proc Natl Acad Sci USA 2005; 102:17448-53.
15. Christoph F, Weikert S, Kempkensteffen C, Krause H, Schostak M, Kollermann J, et al. Promoter hypermethylation profile of kidney cancer with new proapoptotic p53 target genes and clinical implications. Clin Cancer Res 2006; 12:5040-6.
16. Christoph F, Kempkensteffen C, Weikert S, Kollermann J, Krause H, Miller K, et al. Methylation of tumour suppressor genes APAF-1 and DAPK-1 and in vitro effects of demethylating agents in bladder and kidney cancer. Br J Cancer 2006; 95:1701-7.
17. Christoph F, Hinz S, Kempkensteffen C, Schostak M, Schrader M, Miller K. mRNA expression profiles of methylated APAF-1 and DAPK-1 tumor suppressor genes uncover clear cell renal cell carcinomas with aggressive phenotype. J Urol 2007; 178:2655-9.
18. Warburton HE, Brady M, Vlatkovic N, Linehan WM, Parsons K, Boyd MT. p53 regulation and function in renal cell carcinoma. Cancer Res 2005; 65:6498-503.
19. Noon AP, Vlatkovic N, Polanski R, Maguire M, Shawki H, Parsons K, et al. p53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets? Cancer 2010; 116:780-90.
20. Haitel A, Wiener HG, Baethge U, Marberger M, Susani M. mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parameters. Clin Cancer Res 2000; 6:1840-4.
21. Patel S, Player MR. Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer. Expert Opin Investig Drugs 2008; 17:1865-82.
22. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303:844-8.
23. Shangary S, Qin D, McEachern D, Liu M, Miller RS, Qiu S, et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci USA 2008; 105:3933-8.
24. Verma R, Rigatti MJ, Belinsky GS, Godman CA, Giardina C. DNA damage response to the Mdm2 inhibitor nutlin-3. Biochem Pharmacol 2010; 79:565-74.
25. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75:817-25.
26. El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994; 54:1169-74.
27. Lu C, El-Deiry WS. Targeting p53 for enhanced radioand chemo-sensitivity. Apoptosis 2009; 14:597-606.
28. Stickle NH, Cheng LS, Watson IR, Alon N, Malkin D, Irwin MS, et al. Expression of p53 in renal carcinoma cells is independent of pVHL. Mutat Res 2005; 578:23-32.
29. Oberling C, Riviere M, Haguenau F. Ultrastructure of the clear cells in renal carcinomas and its importance for the demonstration of their renal origin. Nature 1960; 186:402-3.
30. Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H, et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci USA 2006; 103:1888-93.
31. Levesque AA, Kohn EA, Bresnick E, Eastman A. Distinct roles for p53 transactivation and repression in preventing UCN-01-mediated abrogation of DNA damage-induced arrest at S and G2 cell cycle checkpoints. Oncogene 2005; 24:3786-96.
32. 2 arrest. Mol Cancer Ther 2008; 7:252-62.
33. Huang B, Deo D, Xia M, Vassilev LT. Pharmacologic p53 activation blocks cell cycle progression but fails to induce senescence in epithelial cancer cells. Mol Cancer Res 2009; 7:1497-509.
34. Roberts AM, Watson IR, Evans AJ, Foster DA, Irwin MS, Ohh M. Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells. Cancer Res 2009; 69:9056-64.
35. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 1997; 57:4285-300.
36. Ikediobi ON, Davies H, Bignell G, Edkins S, Stevens C, O'Meara S, et al. Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther 2006; 5:2606-12.
37. Paulsen MT, Starks AM, Derheimer FA, Hanasoge S, Li L, Dixon JE, et al. The p53-targeting human phosphatase hCdc14A interacts with the Cdk1/cyclin B complex and is differentially expressed in human cancers. Mol Cancer 2006; 5:25.
38. Bykov VJ, Issaeva N, Selivanova G, Wiman KG. Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. Carcinogenesis 2002; 23:2011-8.
39. Kolenko V, Uzzo RG, Bukowski R, Bander NH, Novick AC, Hsi ED, et al. Dead or dying: necrosis versus apoptosis in caspase-deficient human renal cell carcinoma. Cancer Res 1999; 59:2838-42.
40. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 2009; 9:400-14.
41. Oda H, Nakatsuru Y, Ishikawa T. Mutations of the p53 gene and p53 protein overexpression are associated with sarcomatoid transformation in renal cell carcinomas. Cancer Res 1995; 55:658-62.